Lonza Group AG
http://www.lonza.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lonza Group AG
Jazz Nabs Novel Narcolepsy Drug From Sumitomo
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
From Antibodies To Vaccines: How Prestige BioPharma Is Shaping Its Future
The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.
Trade Group Calls For mRNA Vaccines As Guangzhou Starts Lock Downs
Following Shanghai, China’s third-largest city Guangzhou is now on high alert as Omicron cases spread, while pharma and biotech face severe production and supply chain disruptions.
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Company Information
- Industry
- Contract Research Organization-CRO
- Diversified
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
- Contract Manufacturing Organization
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Algonomics NV
- Capsugel S.A.
- HansaBioMed Life Sciences OÜ
- InterHealth Nutraceuticals, Inc.
- Lonza Group Ltd.
- MODA Technology
- Micro-Macinazione S.A.
- PharmaCell B.V.